These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

866 related articles for article (PubMed ID: 29183287)

  • 21. Prevalence of hepatitis B and C viruses in HIV-positive patients in China: a cross-sectional study.
    Xie J; Han Y; Qiu Z; Li Y; Li Y; Song X; Wang H; Thio CL; Li T
    J Int AIDS Soc; 2016; 19(1):20659. PubMed ID: 26979535
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIV, hepatitis C virus, and hepatitis B virus co-infections among injecting drug users in Tehran, Iran.
    Rahimi-Movaghar A; Razaghi EM; Sahimi-Izadian E; Amin-Esmaeili M
    Int J Infect Dis; 2010 Jan; 14(1):e28-33. PubMed ID: 19464218
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population-based prevalence of hepatitis B and C virus, HIV, syphilis, gonorrhoea and chlamydia in male injection drug users in Lagos, Nigeria.
    Tun W; Vu L; Adebajo SB; Abiodun L; Sheehy M; Karlyn A; Njab J; Ahonsi B; Issa BK; Idogho O
    Int J STD AIDS; 2013 Aug; 24(8):619-25. PubMed ID: 23970571
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sero-prevalence of Hepatitis B and C viral co-infections among HIV-1 infected ART-naïve individuals in Kumasi, Ghana.
    Boateng R; Mutocheluh M; Dompreh A; Obiri-Yeboah D; Odame Anto E; Owusu M; Narkwa PW
    PLoS One; 2019; 14(4):e0215377. PubMed ID: 31002687
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence of and risk factors for hepatitis C virus antibody among people who inject drugs in Cambodia: a national biological and behavioral survey.
    Yi S; Mun P; Chhoun P; Chann N; Tuot S; Mburu G
    Harm Reduct J; 2019 Apr; 16(1):29. PubMed ID: 31036011
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High burden of hepatitis C & HIV co-infection among people who inject drugs in Manipur, Northeast India.
    Kermode M; Nuken A; Medhi GK; Akoijam BS; Sharma HU; Mahanta J
    Indian J Med Res; 2016 Mar; 143(3):348-56. PubMed ID: 27241649
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug use and risk behaviour profile, and the prevalence of HIV, hepatitis C and hepatitis B among people with methamphetamine use in Iran.
    Moradi G; Hajarizadeh B; Rahmani K; Mohamadi-Bolbanabad A; Darvishi S; Zareie B; Zavareh FA; Sharafi H; Alavian SM; Ramazani R; Eftekhar M; Radfar SR; Piroozi B; Gouya MM
    Int J Drug Policy; 2019 Nov; 73():129-134. PubMed ID: 31654935
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence and behavioural risks for HIV and HCV infections in a population of drug users of Dakar, Senegal: the ANRS 12243 UDSEN study.
    Leprêtre A; Ba I; Lacombe K; Maynart M; Toufik A; Ndiaye O; Kane CT; Gozlan J; Tine J; Ndoye I; Raguin G; Girard PM
    J Int AIDS Soc; 2015; 18(1):19888. PubMed ID: 26004637
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatitis C, B, and human immunodeficiency virus infections in illicit drug users in Israel: prevalence and risk factors.
    Loebstein R; Mahagna R; Maor Y; Kurnik D; Elbaz E; Halkin H; Olchovsky D; Ezra D; Almog S
    Isr Med Assoc J; 2008 Nov; 10(11):775-8. PubMed ID: 19070285
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk behaviors and HIV, hepatitis B, and hepatitis C seroprevalence among injection drug users in Georgia.
    Shapatava E; Nelson KE; Tsertsvadze T; del Rio C
    Drug Alcohol Depend; 2006 Apr; 82 Suppl 1():S35-8. PubMed ID: 16769443
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence of occult hepatitis B & C in HIV patients infected through sexual transmission.
    Rai RR; Mathur A; Mathur D; Udawat HP; Nepalia S; Nijhawan S; Mathur A
    Trop Gastroenterol; 2007; 28(1):19-23. PubMed ID: 17896605
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Seroprevalence of hepatitis B virus and hepatitis C virus co-infection among people living with HIV/AIDS visiting antiretroviral therapy centres in Nepal: a first nationally representative study.
    Ionita G; Malviya A; Rajbhandari R; Schluter WW; Sharma G; Kakchapati S; Rijal S; Dixit S
    Int J Infect Dis; 2017 Jul; 60():64-69. PubMed ID: 28483724
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatitis B virus and hepatitis C virus infection among HIV-1-infected injection drug users in Dali, China: prevalence and infection status in a cross-sectional study.
    Dong Y; Qiu C; Xia X; Wang J; Zhang H; Zhang X; Xu J
    Arch Virol; 2015 Apr; 160(4):929-36. PubMed ID: 25616842
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Seroprevalence of hepatitis B and C viruses and risk factors in HIV infected children at the Felgehiwot referral hospital, Ethiopia.
    Abera B; Zenebe Y; Mulu W; Kibret M; Kahsu G
    BMC Res Notes; 2014 Nov; 7():838. PubMed ID: 25421947
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of HIV, hepatitis B and hepatitis C and associated risk behaviours amongst injecting drug users in three Afghan cities.
    Nasir A; Todd CS; Stanekzai MR; Bautista CT; Botros BA; Scott PT; Strathdee SA; Tjaden J
    Int J Drug Policy; 2011 Mar; 22(2):145-52. PubMed ID: 21146392
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Co-infection by human immuno deficiency virus, hepatitis B and hepatitis C virus in injecting drug users.
    Devi KhS; Brajachand N; Singh HL; Singh YM
    J Commun Dis; 2005 Mar; 37(1):73-7. PubMed ID: 16637404
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trends in hepatitis B virus, hepatitis C virus, and human immunodeficiency virus prevalence, risk behaviors, and preventive measures among Seattle injection drug users aged 18-30 years, 1994-2004.
    Burt RD; Hagan H; Garfein RS; Sabin K; Weinbaum C; Thiede H
    J Urban Health; 2007 May; 84(3):436-54. PubMed ID: 17356901
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review.
    Degenhardt L; Peacock A; Colledge S; Leung J; Grebely J; Vickerman P; Stone J; Cunningham EB; Trickey A; Dumchev K; Lynskey M; Griffiths P; Mattick RP; Hickman M; Larney S
    Lancet Glob Health; 2017 Dec; 5(12):e1192-e1207. PubMed ID: 29074409
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Seroprevalence of hepatitis B, hepatitis C, human immunodeficiency virus, Treponema pallidum, and co-infections among blood donors in Kyrgyzstan: a retrospective analysis (2013-2015).
    Karabaev BB; Beisheeva NJ; Satybaldieva AB; Ismailova AD; Pessler F; Akmatov MK
    Infect Dis Poverty; 2017 Feb; 6(1):45. PubMed ID: 28222792
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trends and factors in human immunodeficiency virus and/or hepatitis C virus testing and infection among injection drug users newly entering methadone maintenance treatment in Guangdong Province, China 2006-2013: a consecutive cross sectional study.
    Liu Y; Liu Y; Zou X; Chen W; Ling L
    BMJ Open; 2017 Jul; 7(7):e015524. PubMed ID: 28710214
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.